

ORAL PRESENTATION

Open Access

Staged subthalamotomy

Jeff Elias

From Current and Future Applications of Focused Ultrasound 2014. 4th International Symposium Washington, D.C, USA. 12-16 October 2014

Background/introduction

A clinical trial is being planned to investigate the management of medication-refractory motor symptoms associated with Parkinson's disease using a unilateral, focused ultrasound subthalamotomy performed in a staged fashion.

Methods

For this study, ten subjects with medication-refractory symptoms or side effects of advanced Parkinson's disease will be enrolled. Each patient will be treated with a "sub-therapeutic" (stage 1) focused ultrasound subthalamotomy and observed for thirty days.

Those who develop severe and involuntary movements, such as hemiballismus, will be excluded from the second stage procedure. For those who tolerate subthreshold lesioning, a second, full subthalamotomy ablation (stage 2) with focused ultrasound will be performed. Validated Parkinson's disease rating scales, cognitive assessments, and MRI will be obtained before and after the procedures.

Published: 30 June 2015

doi:10.1186/2050-5736-3-S1-O6

Cite this article as: Elias: Staged subthalamotomy. *Journal of Therapeutic Ultrasound* 2015 **3**(Suppl 1):O6.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



University of Virginia, Charlottesville, VA, United States

